이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

MK-7684A 선택된 고형 종양이 있는 참여자에게 다른 항암 요법을 포함하거나 포함하지 않음(MK-7684A-005)(KEYVIBE-005)

2026년 9월 3일 업데이트: Merck Sharp & Dohme LLC

Vibostolimab(MK-7684)과 Pembrolizumab(MK-3475)의 공동 형성 MK-7684A에 대한 다기관, 공개 라벨, 2상 바스켓 연구, 선택된 고형 종양이 있는 참가자에서 다른 항암 요법을 포함하거나 포함하지 않음

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.

연구 개요

연구 유형

중재적

등록 (실제)

611

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • North Holland
      • Amsterdam, North Holland, 네덜란드, 1066CX
        • Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 1121)
    • South Holland
      • Rotterdam, South Holland, 네덜란드, 3015 GD
        • Erasmus Medisch Centrum-Medical Oncology ( Site 1122)
      • Tainan, 대만, 704
        • NATIONAL CHENG-KUNG UNI. HOSP.-clinical trial center ( Site 1302)
      • Taipei, 대만, 10002
        • National Taiwan University Hospital-Oncology ( Site 1301)
      • Taipei, 대만, 10449
        • Mackay Memorial Hospital ( Site 1305)
      • Taoyuan, 대만, 333
        • Chang Gung Medical Foundation-Linkou Branch ( Site 1304)
      • Seoul, 대한민국, 03080
        • Seoul National University Hospital-Internal Medicine ( Site 1312)
      • Seoul, 대한민국, 03722
        • Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1311)
      • Seoul, 대한민국, 05505
        • Asan Medical Center ( Site 1313)
      • Berlin, 독일, 12203
        • Charite Universitätsmedizin Berlin Campus Benjamin Franklin ( Site 1171)
    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, 독일, 69120
        • Universitaetsklinikum Heidelberg-Nationales Centrum für Tumorerkrankungen ( Site 1180)
      • Tübingen, Baden-Wurttemberg, 독일, 72076
        • Universitaetsklinikum Tuebingen-Department of Internal Medicine VIII - Medical Oncology, ECTU, Pne
    • Bavaria
      • München, Bavaria, 독일, 81337
        • Klinikum der Universität München Großhadern ( Site 1176)
    • North Rhine-Westphalia
      • Düsseldorf, North Rhine-Westphalia, 독일, 40225
        • Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 1172)
    • Alaska
      • Anchorage, Alaska, 미국, 99508
        • Alaska Womens Cancer Care ( Site 1016)
    • California
      • Duarte, California, 미국, 91010
        • City of Hope Comprehensive Cancer Center ( Site 1001)
      • Orange, California, 미국, 92868-3201
        • University of California, Irvine (UCI) Health - UC Irvine Me-Chao Family Comprehensive Cancer Cente
    • Michigan
      • Detroit, Michigan, 미국, 48201
        • Karmanos Cancer Institute ( Site 1007)
    • New Jersey
      • Basking Ridge, New Jersey, 미국, 07920
        • Memorial Sloan Kettering - Basking Ridge ( Site 1023)
      • Middletown, New Jersey, 미국, 07748
        • Memorial Sloan Kettering - Monmouth ( Site 1022)
      • Montvale, New Jersey, 미국, 07645
        • Memorial Sloan Kettering - Bergen ( Site 1025)
    • New York
      • Commack, New York, 미국, 11725
        • Memorial Sloan Kettering- Commack ( Site 1021)
      • Harrison, New York, 미국, 10604
        • Memorial Sloan Kettering - Westchester ( Site 1020)
      • New York, New York, 미국, 10065
        • Memorial Sloan Kettering Cancer Center ( Site 1002)
      • Uniondale, New York, 미국, 11553
        • Memorial Sloan Kettering - Nassau ( Site 1026)
    • Oklahoma
      • Tulsa, Oklahoma, 미국, 74146
        • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1024)
    • South Dakota
      • Sioux Falls, South Dakota, 미국, 57104
        • Sanford Cancer Center-Gynecologic Oncology ( Site 1015)
    • Texas
      • Houston, Texas, 미국, 77030
        • Houston Methodist Hospital ( Site 1017)
      • Madrid, 스페인, 28027
        • Clinica Universidad de Navarra-Medical Oncology ( Site 1118)
      • Seville, 스페인, 41013
        • HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 1114)
    • Barcelona
      • Hospitalet, Barcelona, 스페인, 08907
        • Instituto Catalan de Oncologia - Hospital Duran i Reynals-Medical Oncology ( Site 1113)
    • Madrid
      • Pozuelo de Alarcón, Madrid, 스페인, 28223
        • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 1117)
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, 스페인, 28034
        • Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1111)
      • Haifa, 이스라엘, 3109601
        • Rambam Health Care Campus-Oncology ( Site 1141)
      • Jerusalem, 이스라엘, 9112001
        • Hadassah Medical Center-Oncology ( Site 1142)
      • Ramat Gan, 이스라엘, 5265601
        • Sheba Medical Center-ONCOLOGY ( Site 1144)
      • Tel Aviv, 이스라엘, 6423906
        • Sourasky Medical Center-Oncology ( Site 1143)
      • Milan, 이탈리아, 20141
        • Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (
      • Naples, 이탈리아, 80131
        • Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Sperimentazioni Cliniche ( Site 1134)
    • Lazio
      • Rome, Lazio, 이탈리아, 00168
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Ginecologia Oncologica ( Site 1136)
    • Lombardy
      • Milan, Lombardy, 이탈리아, 20132
        • Ospedale San Raffaele-Oncologia Medica ( Site 1135)
    • Milano
      • Rozzano, Milano, 이탈리아, 20089
        • Istituto Clinico Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1138)
      • Osaka, 일본, 541-8567
        • Osaka International Cancer Institute ( Site 1323)
      • Tokyo, 일본, 104-0045
        • National Cancer Center Hospital ( Site 1322)
    • Aichi-ken
      • Nagoya, Aichi-ken, 일본, 464-8681
        • Aichi Cancer Center Hospital ( Site 1324)
    • Chiba
      • Kashiwa, Chiba, 일본, 277-8577
        • National Cancer Center Hospital East ( Site 1321)
    • Araucania
      • Temuco, Araucania, 칠레, 4800827
        • James Lind Centro de Investigacion del Cancer ( Site 1404)
    • Region M. de Santiago
      • Santiago, Region M. de Santiago, 칠레, 7500921
        • FALP-UIDO ( Site 1401)
      • Santiago, Region M. de Santiago, 칠레, 7510032
        • Oncovida ( Site 1405)
      • Santiago, Region M. de Santiago, 칠레, 8420383
        • Bradfordhill-Clinical Area ( Site 1402)
    • Ontario
      • Kingston, Ontario, 캐나다, K7L 2V7
        • Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 1051)
      • Toronto, Ontario, 캐나다, M5G 2M9
        • Princess Margaret Cancer Centre ( Site 1056)
    • Antioquia
      • Medellín, Antioquia, 콜롬비아, 050030
        • Fundacion Colombiana de Cancerología Clinica Vida ( Site 1422)
    • Atlántico
      • Barranquilla, Atlántico, 콜롬비아, 080020
        • Clinica de la Costa S.A.S. ( Site 1421)
    • Cundinamarca
      • Bogotá, Cundinamarca, 콜롬비아, 111511
        • Instituto Nacional de Cancerología-Clinical Oncology ( Site 1425)
    • Risaralda Department
      • Pereira, Risaralda Department, 콜롬비아, 661001
        • Oncologos del Occidente ( Site 1424)
    • Santander Department
      • Piedecuesta, Santander Department, 콜롬비아, 681017
        • Fundación Cardiovascular de Colombia ( Site 1423)
      • Adana, 터키 (Türkiye), 01250
        • Baskent University Dr. Turgut Noyan Research and Training Center ( Site 1201)
      • Ankara, 터키 (Türkiye), 06230
        • Hacettepe Universitesi-oncology hospital ( Site 1209)
      • Ankara, 터키 (Türkiye), 06800
        • Ankara City Hospital-Medical Oncology ( Site 1202)
      • Edirne, 터키 (Türkiye), 22030
        • Trakya University-Medical Oncology ( Site 1207)
      • Istanbul, 터키 (Türkiye), 34303
        • Acibadem Universitesi Atakent Hastanesi ( Site 1208)
      • Istanbul, 터키 (Türkiye), 34722
        • TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1204)
    • Istanbul
      • Istanbul- Fatih, Istanbul, 터키 (Türkiye), 34098
        • Istanbul Universitesi Cerrahpasa ( Site 1203)
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, 폴란드, 02-781
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 1101
    • Pomeranian Voivodeship
      • Gdansk, Pomeranian Voivodeship, 폴란드, 80-952
        • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 1103)
    • West Pomeranian Voivodeship
      • Koszalin, West Pomeranian Voivodeship, 폴란드, 75-581
        • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1104)
      • Paris, 프랑스, 75248
        • Institut Curie ( Site 1152)
    • Auvergne-Rhône-Alpes
      • Lyon, Auvergne-Rhône-Alpes, 프랑스, 69373 Cedex 08
        • CENTRE LEON BERARD-Medical oncology ( Site 1151)
    • Cote-d Or
      • Dijon, Cote-d Or, 프랑스, 21079
        • Centre Georges François Leclerc ( Site 1155)
    • Herault
      • Montpellier, Herault, 프랑스, 34298
        • Institut Regional du Cancer Montpellier ( Site 1157)
    • Paris
      • Villejuif, Paris, 프랑스, 94800
        • Gustave Roussy-medicine departement ( Site 1153)
    • Vaucluse
      • Avignon, Vaucluse, 프랑스, 84000
        • Sainte Catherine Institut du Cancer Avignon Provence-Oncologie médicale ( Site 1156)

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • One of the following histologically or cytologically confirmed, advanced (unresectable or metastatic) solid tumors:

    • Squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix
    • Endometrial cancer
    • Head and neck squamous cell carcinoma (HNSCC)
    • Unresectable biliary adenocarcinoma (gallbladder or biliary tree [intrahepatic or extrahepatic] cholangiocarcinoma)
    • Adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction (GEJ).
    • Triple-negative breast cancer (TNBC)
    • Hepatocellular carcinoma (HCC)
    • Urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra
    • Ovarian cancer
    • Gastric cancer
  • Measurable disease per RECIST v1.1 as assessed by BICR or local site investigator.

  • Adequately controlled blood pressure (BP) with or without antihypertensive medications.

  • Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART).

  • Male participants must agree to follow contraceptive guidance.

  • Female participants are not pregnant or breastfeeding, not a woman of child-bearing potential (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance.

  • Adequate organ function.

Exclusion Criteria:

  • History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
  • Prior therapy with anti-programmed cell-death (PD-1), anti-PD-L1, anti-PD-L2, or anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) agent.
  • Prior systemic anticancer therapy including investigational agents within 4 weeks before randomization/allocation.
  • Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.
  • Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study medication.
  • Active autoimmune disease that has required systemic treatment in past 2 years.
  • Active infection requiring systemic therapy.
  • Concurrent active hepatitis B and hepatitis C virus infection.
  • History of allogenic tissue/solid organ transplant.
  • Previous treatment with lenvatinib (for participants who will receive lenvatinib in their assigned treatment arm).
  • Has clinically significant cardiovascular disease within 12 months from first dose of study intervention.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Pembrolizumab/Vibostolimab Co-Formulation

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion every 3 weeks (Q3W) up to 35 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy.

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

다른 이름들:
  • MK-7684A

Pembrolizumab 200 mg administered via IV infusion Q3W.

다른 이름들:
  • MK-3475
  • 키트루다®
실험적: Pembrolizumab

Participants receive pembrolizumab 200 mg via IV infusion Q3W up to 35 cycles.

Pembrolizumab 200 mg administered via IV infusion Q3W.

다른 이름들:
  • MK-3475
  • 키트루다®
실험적: Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Endometrial Cancer Cohort)

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 20 mg once daily (qd) up to 45 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Lenvatinib.

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

다른 이름들:
  • MK-7684A

Pembrolizumab 200 mg administered via IV infusion Q3W.

다른 이름들:
  • MK-3475
  • 키트루다®

Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD

다른 이름들:
  • E7080
  • 렌비마
  • MK-7902
실험적: Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Hepatocellular Cancer Cohort)

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 12 mg (body weight [BW] ≥60 kg) or lenvatinib 8 mg (BW <60 kg) qd up to 45 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Lenvatinib.

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

다른 이름들:
  • MK-7684A

Pembrolizumab 200 mg administered via IV infusion Q3W.

다른 이름들:
  • MK-3475
  • 키트루다®

Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD

다른 이름들:
  • E7080
  • 렌비마
  • MK-7902
실험적: Pembrolizumab/Vibostolimab + 5-Fluorouracil + Cisplatin

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W, plus 5-fluorouracil (5-FU), plus Cisplatin as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with 5-Fluorouracil + Cisplatin.

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

다른 이름들:
  • MK-7684A

Pembrolizumab 200 mg administered via IV infusion Q3W.

다른 이름들:
  • MK-3475
  • 키트루다®

5-FU 800 mg/m^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles

다른 이름들:
  • 5-FU
  • 플루라실

Cisplatin administered via IV infusion

다른 이름들:
  • 플라티놀
  • 시스 플래티넘
실험적: Pembrolizumab/Vibostolimab Co-Formulation + Paclitaxel

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus paclitaxel as background therapy until meeting discontinuation criteria. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Paclitaxel.

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

다른 이름들:
  • MK-7684A

Pembrolizumab 200 mg administered via IV infusion Q3W.

다른 이름들:
  • MK-3475
  • 키트루다®

Paclitaxel administered via IV infusion at investigator's choice of dose

다른 이름들:
  • 탁솔
  • 아브락산
  • 안자탁스
실험적: Pembrolizumab/Vibostolimab Co-Formulation + Gemcitabine/Cisplatin

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus gemcitabine (until disease progression or unacceptable toxicity) and cisplatin (up to 8 cycles) as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Gemcitabine/Cisplatin

Pembrolizumab 200 mg administered via IV infusion Q3W.

다른 이름들:
  • MK-3475
  • 키트루다®

Cisplatin administered via IV infusion

다른 이름들:
  • 플라티놀
  • 시스 플래티넘

Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity

실험적: Pembrolizumab/Vibostolimab Co-Formulation+ Carboplatin/Paclitaxel/Bevacizumab

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus carboplatin, paclitaxel, and bevacizumab as local standard of care (SOC) background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Carboplatin/Paclitaxel/Bevacizumab.

Pembrolizumab 200 mg administered via IV infusion Q3W.

다른 이름들:
  • MK-3475
  • 키트루다®

Paclitaxel administered via IV infusion at investigator's choice of dose

다른 이름들:
  • 탁솔
  • 아브락산
  • 안자탁스

Carboplatin administered via IV infusion at investigator's choice of dose and frequency

For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles

Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles

실험적: Pembrolizumab/Vibostolimab Co-Formulation + Capecitabine/Oxaliplatin

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus capecitabine and oxaliplatin as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Capecitabine/Oxaliplatin.

Pembrolizumab 200 mg administered via IV infusion Q3W.

다른 이름들:
  • MK-3475
  • 키트루다®

Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles

Oxaliplatin administered via IV infusion Q3W up to 35 cycles

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) in Cohort A1
기간: Up to approximately 24 months

ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 was presented. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). The ORR was calculated using the Miettinen & Nurminen method stratified by prior bevacizumab use interactive voice response system (IVRS). ORR as assessed by BICR in Cohort A1 is presented.

Up to approximately 24 months
Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR in Cohort A1
기간: Up to approximately 24 months

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS as assessed by BICR in Cohort A1 is presented.

Up to approximately 24 months
ORR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
기간: Up to approximately 24 months

ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR in selected solid tumors as assessed by investigator based on RECIST 1.1 is presented. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). Per protocol, Cohort A1 and Cohort I were excluded in the analysis. ORR as assessed by Investigator based on RECIST 1.1 is presented.

Up to approximately 24 months
Progression Free Survival (PFS) Per RECIST 1.1 as Assessed by Investigator at 9 Months
기간: 9 months

PFS is defined as the time from the first dose of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS-9 is defined as the proportion of participants free of documented progression per RECIST 1.1 by investigator or death due to any cause at 9 months from the first dose of study intervention. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS at 9 months as assessed by Investigator based on RECIST 1.1 in Cohort I is presented.

9 months
PFS Per RECIST 1.1 as Assessed by Investigator at 12 Months
기간: 12 months

PFS is defined as the time from the first dose of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS-12 is defined as the proportion of participants free of documented progression per RECIST 1.1 by investigator or death due to any cause at 12 months from the first dose of study intervention. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS at 12 months as assessed by Investigator based on RECIST 1.1 in Cohort I is presented.

12 months

2차 결과 측정

결과 측정
측정값 설명
기간
Overall Survival (OS) in Participants With Selected Solid Tumors
기간: Up to approximately 46 months

For Cohort A1 OS is defined as the time from randomization to death due to any cause. For Cohort A2 to Cohort J OS is defined as the time from the first dose of study intervention to death due to any cause. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. OS in selected solid tumors is presented.

Up to approximately 46 months
PFS Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
기간: Up to approximately 46 months

PFS is defined as the time from first dose of study treatment to the first documented PD or death due to any cause, whichever occurs first per RECIST 1.1 by Investigator for Cohort A2 to J. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed Investigator in Cohort A2 to J is presented.

Up to approximately 46 months
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR in Cohort A1
기간: Up to approximately 46 months

For participants who demonstrate a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by BICR was presented for participants in Cohort A1.

Up to approximately 46 months
DOR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
기간: Up to approximately 46 months

For participants who demonstrate a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by Investigator was presented.

Up to approximately 46 months
ORR Per RECIST 1.1 as Assessed by Investigator in Cohort A1
기간: Up to approximately 24 months

ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by investigator based on RECIST 1.1 in Cohort A1 is presented.

Up to approximately 24 months
PFS Per RECIST 1.1 as Assessed by Investigator in Participants in Cohort A1
기간: Up to approximately 24 months

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PDPer protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS as assessed by Investigator based on RECIST 1.1 in Cohort A1 is presented.

Up to approximately 24 months
Change From Baseline in Global Health Status/Quality of Life Score (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 [EORTC QLQ-C30] Items 29 and 30) in Cohort A1
기간: Baseline and up to Week 12

The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score in Cohort A1 is presented.

Baseline and up to Week 12
Change From Baseline in Physical Functioning Score (EORTC QLQ-C30 Items 1-5) in Cohort A1
기간: Baseline and up to Week 12

The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) score in Cohort A1 is presented.

Baseline and up to Week 12
Number of Participants Who Experienced One or More Adverse Events (AEs)
기간: Up to approximately 46 months

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that experienced at least one AE was reported for each treatment arm.

Up to approximately 46 months
Number of Participants Who Discontinued Study Intervention Due to an AE
기간: Up to approximately 46 months

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that discontinued any study drug due to an AE was reported for each treatment arm.

Up to approximately 46 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Medical Director, Merck Sharp & Dohme LLC

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 9월 16일

기본 완료 (실제)

2025년 8월 5일

연구 완료 (실제)

2025년 8월 5일

연구 등록 날짜

최초 제출

2021년 8월 10일

QC 기준을 충족하는 최초 제출

2021년 8월 10일

처음 게시됨 (실제)

2021년 8월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 28일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 3일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • 7684A-005
  • MK-7684A-005 (기타 식별자: MSD)
  • jRCT2031210335 (레지스트리 식별자: jRCT)
  • KEYVIBE-005 (기타 식별자: MSD)
  • 2021-001009-56 (EudraCT 번호)
  • U1111-1291-4290 (레지스트리 식별자: UTN)
  • 2023-505284-36-00 (레지스트리 식별자: EU CT)
  • 2023 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다